Multiple Sclerosis Therapeutics: Market Research Report

April 2010 | 430 pages | ID: M171B48860CEN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Multiple Sclerosis Therapeutics in US$ Billion.

The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2006 through 2015.

The report profiles 45 companies including Bayer Schering Pharma AG, Biogen Idec Inc., Elan Pharmaceuticals, Inc., Genzyme Corp, Merck Serono SA, Novartis AG, Sanofi-Aventis SA, and Teva Pharmaceuticals Industries Limited.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.MARKET HIGHLIGHTS

Market Snapshots
Market Drivers
Market Restraints
Major Players

2.MARKET OVERVIEW

Increasing Prevalence of Multiple Sclerosis

Table 1. World Multiple Sclerosis Prevalence in Thousands by Select Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)

Table 2. Prevalence by Types of Multiple Sclerosis (includes corresponding Graph/Chart)

MS Therapeutics in the Market
Key Multiple Sclerosis Drugs
Interferon Drugs
Beta Interferon Drugs in Multiple Sclerosis Treatment
Non-Interferon Drugs
Non-Interferon Drugs in Multiple Sclerosis Treatment
High Unmet Need and Rich Pipeline to Expand MS Market
Challenges Ahead

3.MARKET TRENDS

Interferon-based Drugs Dominate Multiple Sclerosis Market
Sales Dip Inevitable for Current Therapies
Tough Times Ahead for Betaseron
Oral Drugs in Pipeline to Alter Market Dynamics in MS Therapies
Competitive Landscape

Table 3. Global Multiple Sclerosis Market by Leading Drugs (2008 & 2009): Percentage Share Breakdown for Copaxone, Avonex, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart)

4.MULTIPLE SCLEROSIS - DRUG PIPELINE

Recent Clinical Trial Activity – An Overview
Drugs Under Development for Treating Multiple Sclerosis
FTY 720 (Fingolimod)
Mylinax
Laquinimod
Alemtuzumab
Teriflunomide
BG-12 (Oral Fumarate)

MN-166

Rituxan/MabThera (Rituximab)
Vaccines for Multiple Sclerosis

5.PRODUCT OVERVIEW

Definition
Causes of Multiple Sclerosis
Different Forms of Multiple Sclerosis
Pathology

6.RECENT INDUSTRY ACTIVITY

Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to treat Multiple Sclerosis
Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA
Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of MS
Novartis Obtains FDA Approval for Extavia
Merck Serono Collaborates with Brigham and Women's Hospital to Extend Multiple Sclerosis Research
Merck Serono Announces Encouraging Phase III Results of Oral Mylinax
Merck Serono Acquires Rights to Apitope’s Multiple Sclerosis Approach
Teva and Active Biotech Obtains Fast Track Status from FDA for Oral Laquinimod
Genzyme Signs an Agreement with Bayer Healthcare
EMD Serono to Set Up Research Facility in Massachusetts
EMD Serono Enters into a Partnership with Fast Forward
Biogen Idec Secures US-FDA Approval for Production Process of TYSABRI®
Biogen Idec Secures Fast Track Designation from US-FDA for PEGylated Interferon Beta-1a
Bayer Schering Pharma Receives SFDA of China Approval for Betaferon®
Merck Serono Signs an Agreement with Bionomics
Orasi Medical Establishes New Office in Tokyo
Merck Serono and Ambrx to Extend Collaboration for Multiple Sclerosis
Kineta Acquires Novel Therapeutic Compounds from Airmid
MediciNova Enters into Agreement with Avigen
Biogen Idec Takes Over Facet Biotech
Teva Pharmaceutical Industries to Take over CoGenesys
Merck Serono Introduces RebiSmartTM Electronic Injection Device
Bayer to Launch Betaferon Titration Pack
MediciNova Announces Phase II Clinical Trial Results of MN-166
The Myelin Repair Foundation Signs Strategic Deal with Dalton Pharma Services
Acorda Therapeutics Takes Over Neurorecovery
Bayer to Introduce 30-Gauge Needle for Betaferon®
Biogen Idec Commences Late-Stage Trial of Oral Compound Bg-12
Bayer Acquires Biologics Manufacturing Plant from Novartis

7.FOCUS ON SELECT PLAYERS

Bayer Schering Pharma AG (Germany)
Biogen Idec Inc. (US)
Elan Pharmaceuticals, Inc. (US)
Genzyme Corp. (US)
Merck Serono SA (Switzerland)
Novartis AG (Switzerland)
Sanofi-Aventis SA (France)
Teva Pharmaceuticals Industries Limited (Israel)

8.GLOBAL MARKET PERSPECTIVE

Table 4. World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 5. World 10-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

Table 6. World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Leading Drugs – Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 7. World 10-year Perspective for Multiple Sclerosis Therapeutics by Leading Drugs – Percentage Breakdown of Dollar Sales for Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. MARKET ANALYSIS

Overview

Table 8. US Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)

Strategic Corporate Developments
Key Players
Biogen Idec, Inc.
Elan Pharmaceuticals, Inc.
EMD Serono, Inc.
Genzyme Corp.

B. MARKET ANALYTICS

Table 9. US Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

2.JAPAN

A. MARKET ANALYSIS

Overview

Table 10. Japanese Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)

Strategic Corporate Development

B. MARKET ANALYTICS

Table 11. Japanese Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

3.EUROPE

A. MARKET ANALYSIS

Overview

Table 12. Multiple Sclerosis Prevalence in Select European Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)

Low Penetration to Fuel Growth in European MS DMDs Market
Oral Medication for MS in Near Future
Strategic Corporate Development
Key Players
Bayer Schering Pharma AG (Germany)
Merck Serono SA (Switzerland)
Novartis AG (Switzerland)
Sanofi-Aventis SA (France)

B. MARKET ANALYTICS

Table 13. European Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

4.REST OF WORLD

A. MARKET ANALYSIS

Overview
Increasing Incidence of Multiple Sclerosis in Canada
Strategic Corporate Developments
Key Player
Teva Pharmaceuticals Industries Limited (Israel)

B. MARKET ANALYTICS

Table 14. Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 45 (including Divisions/Subsidiaries - 51)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East